IX Biopharma    Last:0.345    -0.015

iX Biopharma

No views on Medtecs. Just read that IX is entering the billion dollars Australian cannabis market. The company looks potentially good in the long run with entry to China and Australia market. One to look out for in the future.

chanbs      ( Date: 29-Apr-2020 07:56) Posted: Thanks for sharing whats your view on Medtecs ? WL123456      ( Date: 28-Apr-2020 19:55) Posted: Chan this one got news so likely BB doing flushing. But I am not sure what the contract detail is about. Someone send me in Chinese and I know nuts about Chinese. Hence I have nfi what is going on except that that perhaps it?s good news. If so, it ran from $0.20. Just for your info

 

Check out the chart of Aurora Cannabis, and Cann Group

Aurora Cannabis:
https://finance.yahoo.com/quote/ACB?p=ACB

Cann Group:
https://finance.yahoo.com/quote/CAN.AX?ltr=1
 

 

HUAT AH !!! faster go and buy in 

 

All the pharma stocks are really scary, up fast but down also fast and it seems to be coordinated. Don't forget tomorrow is last day of trading for the week.

 

29.5 cent 

chipchip66      ( Date: 29-Apr-2020 08:57) Posted: viagra mode on.. 28.5c now

 

later got shorties fry also

 

viagra mode on.. 28.5c now

 

and its not a one time usage!

 

it will definitely take a while but yes looking at that price long term for sure!!

SmallSmall      ( Date: 29-Apr-2020 08:55) Posted: If this company can sell its viagra and cannabis well it could be a $0.50 to a $1 stock :)

 

If this company can sell its viagra and cannabis well it could be a $0.50 to a $1 stock :)

 

So good news.

 

those who loaded yesterday huat!!!

 

Premarket at 27c..

 

wah so release good news again???

 

sorry for the " baiting" haha

shortking      ( Date: 28-Apr-2020 15:34) Posted: stop baiting todays fund outflow is all out shows retails in and even ystd funds out were higher  dollarsense      ( Date: 28-Apr-2020 15:15) Posted: Anyways the way price moving at least BB still in this

 

Omg. Strike 1st prize lottery again? So fast? No wonder so much accumulation in the morning yesterday by the BB. Huat 888. Good luck  

SmallSmall      ( Date: 29-Apr-2020 07:52) Posted: 2Nd Round :) Chiong ah ! Already said it is not a one product company ....   NEWS RELEASE iX Biopharma inks agreement with Cannatrek to supply XativaTM, the world&rsquo s first freeze-dried sublingual medicinal cannabis wafer, to the Australian market  XativaTM, which contains a nano-emulsion of broad-spectrum CBD (cannabidiol) delivered using the Group&rsquo s patented WaferiX sublingual delivery technology, is a highly differentiated and superior dosage form that improves bioavailability of CBD, providing patients with rapid absorption, faster therapeutic action and predictable outcome  Cannatrek, a fully licensed medicinal cannabis enterprise with an extensive global wholesale and national distribution network in Australia will distribute XativaTM to pharmacies across Australia  The supply to Cannatrek marks the Group&rsquo s official entry into the high-growth Australian cannabis market which is expected to grow from US$0.04 billion in 2020 to US$1.23 billion by 2024 Singapore, 29 April 2020 &ndash Specialty pharmaceutical company iX Biopharma Ltd (SGX:42C) (&ldquo iX Biopharma&rdquo or, together with its subsidiaries, &ldquo the Group&rdquo ) is pleased to announce that its wholly-owned subsidiary, iX Syrinx (&ldquo Syrinx&rdquo ), has formalised a supply agreement with Cannatrek Medical Pty Ltd (&ldquo Cannatrek&rdquo ), a wholly-owned subsidiary of Cannatrek Ltd. Cannatrek is a medicinal cannabis enterprise with a national distribution network in Australia and participates heavily in doctor and patient education programmes for medicinal cannabis. The existing delivery forms available in the market today suffer from the lack of fixed unit dosages, inconsistent absorption and variable or poor bioavailability. Leveraging on iX Biopharma&rsquo s novel and patented WaferiXTM sublingual delivery technology, the Group has developed XativaTM to address this gap in the market. Together with Cannatrek, the Group will commence supply and distribution activities of XativaTM, the Group&rsquo s proprietary medicinal CBD (cannabidiol) sublingual wafer, to pharmacies across Australia. XativaTM will be prescribed by medical practitioners to patients via the Special Access Scheme and Authorised Prescriber pathway administered by the Therapeutic Goods Administration (&ldquo TGA&rdquo ) of Australia. Tommy Huppert, CEO of Cannatrek said: &ldquo Driven by our commitment to provide patients with safe, affordable and effective treatments, our partnership with iX Biopharma has been a natural progression in our growth journey. Built upon the novel and patented WaferiX technology, Xativa, through its unique and superior sublingual dosage form, is well-positioned to disrupt the current market of medicinal cannabis products.&rdquo Ms Eva Tan, Director of Corporate and Commercial Strategy of iX Biopharma said: &ldquo We are excited to partner with leaders like Cannatrek to reach Australian patients through their well-established network of prescribers and pharmacies. Patients are now more knowledgeable about the advantages of sublingually administered cannabis medicines in increasing bioavailability and improving patient outcomes. We are confident that our sublingual technology, which is clinically proven and widely used across our pharmaceutical and nutraceutical product portfolio, will allow us to better serve patient need and expectation.&rdquo 1 (Co. Reg. No: 200405621W)   (Co. Reg. No: 200405621W) Today, the legalisation and widespread use of cannabis and cannabinoids around the world is happening at an unprecedented pace. CBD in particular, one of the primary non-intoxicating compounds found in the cannabis plant, has attracted growing interest due to its safety and efficacy in treating many health conditions, including chronic pain, anxiety, movement and sleep disorders. In view of these prevailing trends, the Australian cannabis market is expected to grow exponentially from an estimated US$0.04 billion in 2020 to US$1.23 billion by 20241. For more information on XativaTM, please refer to the link below: [http://www.ixbiopharma.com/xativa] - The End - About iX Biopharma Ltd iX Biopharma is a specialty pharmaceutical and nutraceutical company listed on the Catalist board of the Stock Exchange of Singapore (SGX-ST), operating a fully integrated business model from drug development to manufacturing and supply, with facilities in Australia. The Group is focused on the development and commercialisation of therapies for diseases of the central nervous system using novel, patent-protected formulations for sublingual delivery. iX Biopharma&rsquo s pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management. iX Biopharma&rsquo s drugs for the treatment of erectile dysfunction, Wafesil, a sublingual sildenafil wafer, and Silcap, have been registered in Australia. iX Biopharma has developed Xativa, the world&rsquo s first freeze-dried sublingual medicinal cannabis wafer. The Group&rsquo s nutraceuticals division, Entity Health Limited, is engaged in the development and commercialisation of nutraceutical products that address specific conditions and improve quality of life. It distributes its Entity line of nutraceutical products through more than 200 pharmacies and health food shops in Australia and online. About Cannatrek Ltd Cannatrek is a fully licensed medicinal cannabis enterprise in Australia, operating as a first-mover in the nascent medical cannabis industry, with licences in hand to operate from seed to patient. Cannatrek is developing complete vertical integration, from biomedical research and education, cultivation and green technology, through to processing and smart packaging, as well as a secure blockchain to cover end-to-end distribution. More recently, Cannatrek was awarded Major Project Status from the Federal Government for its $160.0 million production facility in the Victorian regional city of Shepparton. When operating at full production, Cannatrek aims to produce 160 tonnes of medicinal cannabis per year, which will make it one of the world&rsquo s largest medicinal cannabis facilities. Cannatrek also has an extensive global wholesale and national distribution network in Australia. For more information, visit http://cannatrek.com.au/ 1 Prohibition Partners, 2020, &ldquo The Oceania Cannabis Report, Second Edition, April 2020&rdquo     2   Contact for media: Dr Janakan Krishnarajah Chief Operating Officer and Chief Medical Officer T: +65 6235 2270 E: [email protected] Investor Relations: Kamal Samuel/James Bywater/Jonathan Wee T: +65 6438 2990 E: [email protected] Eva Tan Director, Corporate and Commercial Strategy T: +65 6235 3212 E: [email protected] (Co. Reg. No: 200405621W)       This announcement has been reviewed by the Company&rsquo s sponsor, CIMB Bank Berhad, Singapore Branch (&ldquo Sponsor&rdquo ) in accordance with Rule 226(2)(b) of the Catalist Rules. This announcement has   not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.   The contact person for the Sponsor is Mr. Yee Chia Hsing, Head, Catalist. The contact particulars are 50 Raffles Place, #09-01 Singapore Land Tower, Singapore 048623, telephone: (65) 6337-5115. 3

 

Thanks for sharing
whats your view on Medtecs ?

WL123456      ( Date: 28-Apr-2020 19:55) Posted: Chan this one got news so likely BB doing flushing. But I am not sure what the contract detail is about. Someone send me in Chinese and I know nuts about Chinese. Hence I have nfi what is going on except that that perhaps it?s good news. If so, it ran from $0.20. Just for your info. chanbs      ( Date: 28-Apr-2020 17:13) Posted: Surprise sell down / shorting today  1 day wonder stock ?

 

wah BB collect damn cheap yesterday!!! sly man haha. 

 

2Nd Round :) Chiong ah ! Already said it is not a one product company ....

  NEWS RELEASE
iX Biopharma inks agreement with Cannatrek to supply XativaTM, the world&rsquo s first freeze-dried sublingual medicinal cannabis wafer, to the Australian market
 XativaTM, which contains a nano-emulsion of broad-spectrum CBD (cannabidiol) delivered using the Group&rsquo s patented WaferiX sublingual delivery technology, is a highly differentiated and superior dosage form that improves bioavailability of CBD, providing patients with rapid absorption, faster therapeutic action and predictable outcome
 Cannatrek, a fully licensed medicinal cannabis enterprise with an extensive global wholesale and national distribution network in Australia will distribute XativaTM to pharmacies across Australia
 The supply to Cannatrek marks the Group&rsquo s official entry into the high-growth Australian cannabis market which is expected to grow from US$0.04 billion in 2020 to US$1.23 billion by 2024
Singapore, 29 April 2020 &ndash Specialty pharmaceutical company iX Biopharma Ltd (SGX:42C) (&ldquo iX Biopharma&rdquo or, together with its subsidiaries, &ldquo the Group&rdquo ) is pleased to announce that its wholly-owned subsidiary, iX Syrinx (&ldquo Syrinx&rdquo ), has formalised a supply agreement with Cannatrek Medical Pty Ltd (&ldquo Cannatrek&rdquo ), a wholly-owned subsidiary of Cannatrek Ltd. Cannatrek is a medicinal cannabis enterprise with a national distribution network in Australia and participates heavily in doctor and patient education programmes for medicinal cannabis.
The existing delivery forms available in the market today suffer from the lack of fixed unit dosages, inconsistent absorption and variable or poor bioavailability. Leveraging on iX Biopharma&rsquo s novel and patented WaferiXTM sublingual delivery technology, the Group has developed XativaTM to address this gap in the market.
Together with Cannatrek, the Group will commence supply and distribution activities of XativaTM, the Group&rsquo s proprietary medicinal CBD (cannabidiol) sublingual wafer, to pharmacies across Australia. XativaTM will be prescribed by medical practitioners to patients via the Special Access Scheme and Authorised Prescriber pathway administered by the Therapeutic Goods Administration (&ldquo TGA&rdquo ) of Australia.
Tommy Huppert, CEO of Cannatrek said: &ldquo Driven by our commitment to provide patients with safe, affordable and effective treatments, our partnership with iX Biopharma has been a natural progression in our growth journey. Built upon the novel and patented WaferiX technology, Xativa, through its unique and superior sublingual dosage form, is well-positioned to disrupt the current market of medicinal cannabis products.&rdquo
Ms Eva Tan, Director of Corporate and Commercial Strategy of iX Biopharma said: &ldquo We are excited to partner with leaders like Cannatrek to reach Australian patients through their well-established network of prescribers and pharmacies. Patients are now more knowledgeable about the advantages of sublingually administered cannabis medicines in increasing bioavailability and improving patient outcomes. We are confident that our sublingual technology, which is clinically proven and widely used across our pharmaceutical and nutraceutical product portfolio, will allow us to better serve patient need and expectation.&rdquo
1
(Co. Reg. No: 200405621W)

  (Co. Reg. No: 200405621W)
Today, the legalisation and widespread use of cannabis and cannabinoids around the world is happening at an unprecedented pace. CBD in particular, one of the primary non-intoxicating compounds found in the cannabis plant, has attracted growing interest due to its safety and efficacy in treating many health conditions, including chronic pain, anxiety, movement and sleep disorders. In view of these prevailing trends, the Australian cannabis market is expected to grow exponentially from an estimated US$0.04 billion in 2020 to US$1.23 billion by 20241.
For more information on XativaTM, please refer to the link below: [http://www.ixbiopharma.com/xativa]
- The End -
About iX Biopharma Ltd
iX Biopharma is a specialty pharmaceutical and nutraceutical company listed on the Catalist board of the Stock Exchange of Singapore (SGX-ST), operating a fully integrated business model from drug development to manufacturing and supply, with facilities in Australia. The Group is focused on the development and commercialisation of therapies for diseases of the central nervous system using novel, patent-protected formulations for sublingual delivery.
iX Biopharma&rsquo s pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management. iX Biopharma&rsquo s drugs for the treatment of erectile dysfunction, Wafesil, a sublingual sildenafil wafer, and Silcap, have been registered in Australia. iX Biopharma has developed Xativa, the world&rsquo s first freeze-dried sublingual medicinal cannabis wafer.
The Group&rsquo s nutraceuticals division, Entity Health Limited, is engaged in the development and commercialisation of nutraceutical products that address specific conditions and improve quality of life. It distributes its Entity line of nutraceutical products through more than 200 pharmacies and health food shops in Australia and online.
About Cannatrek Ltd
Cannatrek is a fully licensed medicinal cannabis enterprise in Australia, operating as a first-mover in the nascent medical cannabis industry, with licences in hand to operate from seed to patient. Cannatrek is developing complete vertical integration, from biomedical research and education, cultivation and green technology, through to processing and smart packaging, as well as a secure blockchain to cover end-to-end distribution. More recently, Cannatrek was awarded Major Project Status from the Federal Government for its $160.0 million production facility in the Victorian regional city of Shepparton. When operating at full production, Cannatrek aims to produce 160 tonnes of medicinal cannabis per year, which will make it one of the world&rsquo s largest medicinal cannabis facilities. Cannatrek also has an extensive global wholesale and national distribution network in Australia.
For more information, visit http://cannatrek.com.au/
1 Prohibition Partners, 2020, &ldquo The Oceania Cannabis Report, Second Edition, April 2020&rdquo
    2

  Contact for media:
Dr Janakan Krishnarajah
Chief Operating Officer and Chief Medical Officer T: +65 6235 2270
E: [email protected]
Investor Relations:
Kamal Samuel/James Bywater/Jonathan Wee
T: +65 6438 2990
E: [email protected]
Eva Tan
Director, Corporate and Commercial Strategy T: +65 6235 3212
E: [email protected]
(Co. Reg. No: 200405621W)
      This announcement has been reviewed by the Company&rsquo s sponsor, CIMB Bank Berhad, Singapore Branch (&ldquo Sponsor&rdquo ) in accordance with Rule 226(2)(b) of the Catalist Rules. This announcement has
  not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.
  The contact person for the Sponsor is Mr. Yee Chia Hsing, Head, Catalist. The contact particulars are 50 Raffles Place, #09-01 Singapore Land Tower, Singapore 048623, telephone: (65) 6337-5115.
3

 

BB doing flushing so why share price dropping today?